Figure 1.
A, Mean Radiographic Global Impression of Change (RGI-C) rickets and lower-limb deformity score with burosumab vs conventional therapy stratified by prebaseline doses of oral phosphate using published dose thresholds. B, Mean RGI-C rickets and lower-limb deformity score with burosumab vs conventional therapy stratified by prebaseline doses of active vitamin D using published dose thresholds. C, Mean (SE) RGI-C rickets and lower-limb deformity scores with burosumab vs on-study doses of phosphate using published dose thresholds. D, Mean (SE) RGI-C rickets and lower-limb deformity scores with burosumab vs on-study doses of active vitamin D using published dose thresholds. Number above error bar is the mean; error bar denotes SE; number within column is number of patients contributing to the result shown.

A, Mean Radiographic Global Impression of Change (RGI-C) rickets and lower-limb deformity score with burosumab vs conventional therapy stratified by prebaseline doses of oral phosphate using published dose thresholds. B, Mean RGI-C rickets and lower-limb deformity score with burosumab vs conventional therapy stratified by prebaseline doses of active vitamin D using published dose thresholds. C, Mean (SE) RGI-C rickets and lower-limb deformity scores with burosumab vs on-study doses of phosphate using published dose thresholds. D, Mean (SE) RGI-C rickets and lower-limb deformity scores with burosumab vs on-study doses of active vitamin D using published dose thresholds. Number above error bar is the mean; error bar denotes SE; number within column is number of patients contributing to the result shown.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close